BMO Capital Starts Ra Pharma (RARX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- Six killed in cyclone off India's eastern coast
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- SanDisk stock falls ahead of earnings report
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Credit Suisse Starts Ra Pharma (RARX) at Outperform
November 21, 2016 6:57 AM ESTCredit Suisse initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $19.00.
Analyst Kennen MacKay commented, "We view RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria (PNH) with potential to capture >30% market... More
Jefferies Starts Ra Pharma (RARX) at Buy
November 21, 2016 6:51 AM ESTJefferies initiates coverage on Ra Pharma (NASDAQ: RARX) with a Buy rating and a price target of $25.00.
Analyst Eun Yang commented, "Utilizing its peptide chemistry platform, RARX focus on complement-mediated diseases. Given well-validated C5 target & encouraging Ph1 data, we view lead candidate... More



